Hydrofarm Holdings Group Azioni (NASDAQ: HYFM)

Hydrofarm Holdings Group (NASDAQ:HYFM) Azioni

Hydrofarm Holdings Group

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BFLY

HYFM

STIM

Le recenti operazioni degli insider che puntano su queste quattro penny stock. Scopri quali azioni stanno attirando l&#39;attenzione e perché.

4 penny stock sotto la lente d&#39;ingrandimento degli insider

Hydrofarm Holdings Group, Inc. - Common Stock

Hydrofarm Holdings Group Inc

WIIM

WGRX

Wellgistics Health shares are trading higher after the company secured a $50 million equity line of credit facility.

Baird analyst Mircea Dobre maintains Manitowoc Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) with a Neutral and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

Baird Maintains Neutral on Manitowoc Co, Lowers Price Target to $11

&nbsp;– The #1 brand of siding in North America&#x2A; to supply Hardie&#xAE; siding and trim for all new McKinley Homes developments –
CHICAGO, May 8, 2025 /PRNewswire/ -- James Hardie Building Products Inc. (James Hardie), the North American leader in fiber cement siding and exterior solutions and a subsidiary of James Hardie Industries plc ((ASX: JHX, NYSE:<a href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>), today announced a new three-year exclusive agreement with McKinley Homes, one of the top new construction developers in the Southeastern United States. Under the terms of the deal, James Hardie will supply its Hardie&#xAE; siding and trim products for all new McKinley Homes residential communities across Alabama, Tennessee, Georgia, Texas, and North Carolina.

James Hardie Announces 3-Yr Exclusive Agreement With Mckinley Homes To Supply Hardie Siding And Trim Products For All New Mckinley Homes Residential Communities

Wells Fargo analyst Sarah Akers maintains NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) with a Overweight and raises the price target from $43 to $45.

Wells Fargo Maintains Overweight on NiSource, Raises Price Target to $45

KELYA

Kelly Services shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) ("Sadot Group", "Sadot" or the "Company"), an emerging player in the global food supply chain sector, announced today that Catia Jorge has submitted her voluntary resignation due to personal reasons as Chief Executive Officer. Ms. Jorge will remain with the Company as CEO through June 1, 2025.
The Company is pleased to announce that David Hanna, current Executive Vice President, Head of Sadot Canada Inc. will be named Interim CEO effective June 2, 2025.
Mr. Hanna has extensive experience including over two decades of senior management expertise in the global agri-food industry. Mr. Hanna's career spans a number of large and medium growth agri-food and commodity businesses where he has held CEO, CFO and President positions with revenues ranging up to $500 million annually. He has been involved in establishing global operations on five continents, acquiring assets and companies, developing high performing export and trade teams, and financing, designing and executing numerous greenfield and brownfield building and development projects globally.

Management

SDOT

Sadot Group CEO Catia Jorge Resigns; David Hanna Appointed Interim CEO Effective June 2, 2025

International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported better-than-expected earnings for the first quarter, <a href="https://www.benzinga.com/quote/IFF/earnings">after the closing bell on Tuesday.</a>
The company posted quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $1.14 per share. The company reported quarterly sales of $2.84 billion which beat the analyst consensus estimate of $2.83 billion.
&#8220;IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,&#8221; said IFF CEO Erik Fyrwald. &#8220;Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio.&#8221;
Intl Flavors &amp; Fragrances affirmed FY2025 sales guidance of $10.60 billion to $10.90 billion, versus market estimates of $10.87 billion.
Intl Flavors &amp; Fragrances shares dipped 7.1% to close at $73.59 on Wednesday.
These analysts made changes to their price targets on Intl Flavors &amp; Fragrances following earnings announcement.
<ul>
<li>Barclays analyst Lauren Lieberman upgraded Intl Flavors &amp; Fragrances from Equal-Weight to Overweight and raised the price target from $76 to $84.</li>
<li>Baird analyst Ghansham Panjabi maintained the stock with an Outperform rating and lowered the price target from $110 to $100..</li>
</ul>
Considering buying IFF stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08090443/image-2-34-1024x588.png" alt="" class="wp-image-907950" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08090443/image-2-34-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08090443/image-2-34-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08090443/image-2-34-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08090443/image-2-34.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Earnings

These Analysts Revise Their Forecasts On International Flavors & Fragrances After Q1 Results

Wells Fargo analyst David Lantz maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Overweight and raises the price target from $290 to $310.

CVNA

Wells Fargo Maintains Overweight on Carvana, Raises Price Target to $310

ENOV

Enovis shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 adjusted EPS guidance.

Clorox Professional (CloroxPro), the trusted makers of a broad portfolio of healthcare and commercial cleaning solutions, is proud to announce our new contract with Vizient, the nation's largest provider-driven healthcare performance improvement company. This new agreement reflects CloroxPro's commitment to supporting healthcare and cleaning professionals with expanded solutions to meet evolving needs.\
"CloroxPro is eager to bring our 110-year legacy of supporting healthcare professionals to Vizient as we collaborate to deliver exceptional value to their customers," said Dan Kellenberger, General Manager and VP, Clorox Professional. "We are committed to supporting healthcare professionals' dedication to combatting infections by providing cleaning and disinfecting solutions that deliver efficacy and value, as well as education and support for our customers and end-users at every step of their journey."
Under the new Vizient contract, CloroxPro will be providing a broad range of cleaning and disinfecting solutions, including products from trusted brands like Clorox Healthcare, Clorox EcoClean, Pine-Sol and more. The contract is effective as of May 1, 2025, with both companies working closely to ensure a seamless integration of the expanded product offerings.

Contracts

CloroxPro Enters New Agreement With Vizient To Supply Multiple Cleaning And Disinfecting Products

Needham analyst Joshua Reilly reiterates Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) from Hold to Hold.

Reiteration

PAYC

Needham Reiterates Hold on Paycom Softwareto Hold

Wells Fargo analyst Zachary Fadem maintains National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) with a Equal-Weight and raises the price target from $13 to $15.

Wells Fargo Maintains Equal-Weight on National Vision Holdings, Raises Price Target to $15

AXDX

Accelerate Diagnostics shares are trading lower after the company announced it filed for Chapter 11 bankruptcy protection

Rave Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAVE#NASDAQ">RAVE</a>) reported quarterly earnings of $0.05 per share. This is a 25 percent increase over earnings of $0.04 per share from the same period last year. The company reported $2.97 million in sales this quarter. This is a 0.14 percent increase over sales of $2.96 million the same period last year.

RAVE

Rave Restaurant Gr Q3 EPS $0.05 Up From $0.04 YoY, Sales $2.97M Up From $2.96M YoY

Wells Fargo analyst Zachary Fadem maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Overweight and lowers the price target from $445 to $420.

Wells Fargo Maintains Overweight on Home Depot, Lowers Price Target to $420

CTEV

Claritev shares are trading lower after the company reported a Q1 EPS miss.

Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) reported quarterly losses of $(8.45) per share which missed the analyst consensus estimate of $(2.38) by 255.04 percent. This is a 402.98 percent decrease over losses of $(1.68) per share from the same period last year.

Earnings Misses

DWTX

Dogwood Therapeutics Q1 EPS $(8.45) Misses $(2.38) Estimate

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
"At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia."

Treasuries

Wellgistics Health Announces It Has Secured $50M ELOC Facility For XRP Treasury Reserve & Real-Time Payments Infrastructure

Wells Fargo analyst Zachary Fadem maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Overweight and lowers the price target from $285 to $260.

Wells Fargo Maintains Overweight on Lowe's Companies, Lowers Price Target to $260

Baird analyst Mig Dobre maintains Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) with a Outperform and lowers the price target from $188 to $162.

MIDD

Baird Maintains Outperform on Middleby, Lowers Price Target to $162

Press Releases

Water Tower Research Publishes Initiation of Coverage Report on Hydrofarm Holdings Group, Inc. "Best-in-Class Execution in a Long-Term Favorable Growth Category"

Comments

Hydrofarm Holdings Group

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO